Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Journal of Natural Science, Biology, and Medicine|November 19, 2011
Role of antibodies in cancer targetingHusain Attarwala
Pharmaceutical Research|January 28, 2012
Multi-compartmental nanoparticles-in-emulsion formulation for macrophage-specific anti-inflammatory gene deliveryHusain Attarwala, Mansoor Amiji
Advanced Drug Delivery Reviews|December 11, 2012
Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tractChristina Kriegel, Husain Attarwala, Mansoor Amiji
Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology|May 26, 2017
Oral nucleic acid therapy using multicompartmental delivery systemsHusain Attarwala, Murui Han, Jonghan Kim, et al.
Molecular Pharmaceutics|July 25, 2017
Cosilencing Intestinal Transglutaminase-2 and Interleukin-15 Using Gelatin-Based Nanoparticles in an in Vitro Model of Celiac DiseaseHusain Attarwala, Valerie Clausen, Prasoon Chaturvedi, et al.
Nucleic Acid Therapeutics|December 28, 2022
Translational Pharmacokinetic/Pharmacodynamic Model for mRNA-3927, an Investigational Therapeutic for the Treatment of Propionic AcidemiaHusain Attarwala, Matthew Lumley, Min Liang, et al.
Clinical and Translational Science|July 29, 2024
Translational pharmacokinetic/pharmacodynamic model for mRNA-0184, an investigational therapeutic for the treatment of heart failureNeeraj Kaushal, Husain Attarwala, Mir Javid Iqbal, et al.
Journal of Clinical Pharmacology|July 20, 2019
Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) AmyloidosisXiaoping Zhang, Varun Goel, Husain Attarwala, et al.
Antibodies (Basel, Switzerland)|November 22, 2022
Rational Design and In Vivo Characterization of mRNA-Encoded Broadly Neutralizing Antibody Combinations against HIV-1Elisabeth Narayanan, Samantha Falcone, Sayda M Elbashir, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 28, 2026
Immunostimulatory and Immunodynamic Modeling Analysis to Determine a Plausible Starting Dose of mRNA-4359 for Use in First-In-Human TrialsStephen A Greene, Madhav Channavazzala, Bhairav Paleja, et al.
Pageof 2